Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Newer chemotherapeutic agents target extracellular signaling, including the mitogen-activated protein kinase kinase (MEK) pathway. We present a case of a 54-year-old female who developed bilateral multifocal central serous-like chorioretinopathy shortly after starting MEK inhibition for metastatic cutaneous melanoma. There was a complete resolution of findings after drug stoppage. After resuming a lower dose of the MEK inhibitor, the findings recurred again but resolved after drug stoppage. Other etiologies were unlikely given the clinical course. The presumed mechanism involves toxicity to the retinal pigment epithelium, with breakdown of the blood-retinal barrier. Recognition of this side effect is important with this new class of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy, but some of these early-phase trials were stopped prematurely because of toxicity issues, including various ocular adverse effects ( 21 , 68 – 70 ).”
From Loss of Extracellular Signal-Regulated Kinase 1/2 in the Retinal Pigment Epithelium Leads to RPE65 Decrease and Retinal Degeneration (2017) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“Hindawi Publishing Corporation Case Reports in Ophthalmological Medicine Volume 2013, Article ID 673796, 3 pages http://dx.doi.org/10.1155/2013/673796”
BackgroundInfluentialResistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., Aguirre, S., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90
Jiang (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000191 · Cited by 88
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Finn, R. S., Javle, M. M., Tan, B. R., Weekes, C. D., Bendell, J. C., Patnaik, A., Khan, G. N., Laheru, D. A., Anderson, L., Christy‐Bittel, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.220 · Cited by 48
Acute Onset Central Serous Retinopathy In Association With Mek Inhibitor Use For Metastatic Cancer
Vélez-Montoya, R., Olson, J., Petrash, M. J., Messersmith, W. A., Mandava, N., & Oliver, S. C. N. (2011) · Investigative Ophthalmology & Visual Science · Cited by 13
Cited by
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.038 · Cited by 141
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 135
“In a case report on treatment with the MEK inhibitor trametinib, the authors suggested a possible disruption of the pigment epithelial function and, in particular, a loss of barrier functions [21].”
BackgroundOcular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N., Velazquez-Martin, J. P., & Bedard, P. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw100 · Cited by 110
Daud, A., & Tsai, K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 94
Metadata
- Authors
- Schoenberger, S. D., & Kim, S. J.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Kim, Stephen J.
- ORCID
- Kim, Stephen J.
- Venue
- Case Reports in Ophthalmological Medicine
- Publisher
- Hindawi Limited
- Published
- 2013
- Volume
- 2013
- Pages
- 1-3
- ISSN
- 2090-6722 (ISSN-L)
- 2090-6730
- PMC
- PMC3608121
- OpenAlex
- W2054319863
- Cited by
- 46
- References
- 6
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 4 · 2014: 3 · 2013: 1
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Case Reports in Ophthalmological Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Research to Prevent Blindness
- Vanderbilt University
- School of Medicine, Vanderbilt University
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- MEK inhibitors, metastatic cutaneous melanoma, drug-induced retinal toxicity, retinal pigment epithelium, blood-retinal barrier breakdown, MAPK signaling, adverse drug reactions, chemotherapy side effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. https://app.cochat.ai/papers/10.1155/2013/673796
- The paper
- Schoenberger, S. D., & Kim, S. J. (2013). Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. Case Reports in Ophthalmological Medicine. https://doi.org/10.1155/2013/673796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.